LOS ANGELES, CA / ACCESSWIRE / September 10, 2016 / Lundin Law PC (the "Firm") announces a class action lawsuit has been filed against Juno Therapeutics Inc. ("Juno" or the "Company") (JUNO) concerning possible violations of federal securities laws between May 9, 2016 and July 7, 2016 (the "Class Period"). Investors, who purchased or otherwise acquired shares during the Class Period, should contact the Firm in advance of the September 12, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, Juno failed to disclose that a patient died during a clinical trial for its product candidate in May 2016. Juno was thus trading at artificially inflated prices and some insiders participated in heavy selling of shares until July 7, 2016. On July 7, 2016, Juno announced the May 2016 death and two additional deaths during clinical trial, and the Food & Drug Administration put a hold on the trial. After the true details emerged, shares of Juno dropped in value sharply, which caused investors harm.

Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC